enzastaurin + temozolomide
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Trial Timeline
Sep 1, 2006 → Dec 1, 2009
NCT ID
NCT00402116About enzastaurin + temozolomide
enzastaurin + temozolomide is a phase 1/2 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00402116. Target conditions include Glioblastoma, Glioblastoma Multiforme, Gliosarcoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00402116 | Phase 1/2 | Completed |
Competing Products
20 competing products in Glioblastoma